CVRx Reports Strong Q1 2026 Results with 20% Revenue Growth and Reduced Net Loss
CVRX sits 60% above its 52-week low of $4.299.
Summary
CVRx reported robust first-quarter 2026 financial results, with total revenue increasing 20% year-over-year to $14.8 million, driven by a 22% rise in U.S. revenue. The company also saw an improvement in profitability, with net loss narrowing to $13.1 million ($0.50 per share) from $13.8 million ($0.53 per share) in the prior year, alongside a gross margin expansion to 87%. These strong operational and financial metrics, including growth in active implanting centers, indicate successful execution on its growth strategy, building on the positive momentum from its 2025 annual report and recent BENEFIT-HF trial enrollment. Traders will likely view this as a positive indicator of the company's commercial progress and market penetration for its neuromodulation solutions. Investors should monitor continued expansion in U.S. sales territories and the progress of the BENEFIT-HF trial.
At the time of this announcement, CVRX was trading at $6.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $182.9M. The 52-week trading range was $4.30 to $11.30. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.